Thus, the development of strategies to treat CML variants characterized by non-canonical HH signaling may require patient prescreening for resistance to SMO inhibition as well as to combination treatments targeting multiple pathways. Here, SMO is linked to chronic myelogenous leukemia, BCR-ABL1 positive.